Featured Research

from universities, journals, and other organizations

New more effective treatment option for breast cancer patients approved by FDA

Date:
February 22, 2013
Source:
Rush University Medical Center
Summary:
Patients with HER2-positive breast cancer, a particularly aggressive form of breast cancer, now have a new, effective and less toxic therapeutic option. On Feb., 22, the U.S. Food and Drug Administration (FDA) approved the new treatment drug, Kadcyla (trastuzumab emtansine), also known as TDM-1, which combines Traztuzumab, also called Herceptin, with the powerful chemotherapy drug emtansine.

Patients with HER2-positive breast cancer, a particularly aggressive form of breast cancer, now have a new, effective and less toxic therapeutic option.

On Friday, Feb., 22, the Food and Drug Administration (FDA) approved the new treatment drug, Kadcyla (trastuzumab emtansine), also known as TDM-1, which combines Traztuzumab, also called Herceptin, with the powerful chemotherapy drug emtansine.

The drug therapy is developed by Roche-owned Genentech, which funded the study.

Results from clinical trials of the drug TDM-1, known as "Super Herceptin," showed that it was more effective and less toxic than the standard regimen for this type of tumor. The medication kept patients free of disease for longer than the standard chemotherapy regimen.

Rush was one of only two medical centers in Illinois and a small number across the country studying the treatment.

HER-2 positive breast cancer patients have been found to be positive for carrying a protein that promotes the growth of cancer cells. TDM-1 is taken directly to cells that have the HER2 protein on the membrane, such as the cancer cells, while sparing normal cells. This results in less toxicity from the chemotherapy drug.

"TDM-1 works like the original drug Herceptin by hunting down and interfering with the cancer cells," said Dr. Melody Cobleigh, Director of the Comprehensive Breast Center at Rush and lead investigator of the TDM-1 clinical trials at Rush. "But this newer version, called TDM-1, is Herceptin with a chemotherapy drug attached. The combination delivers a one-two punch, seeking out the cancer cells and not only stopping growth but delivering the chemo right to the cell."

"The tumor cell basically eats the TDM-1 and then, the TDM-1 gets released and destroys the tumor cell from the inside out," said Cobleigh.

"The best part for patients is that it is very tolerable and does not have the debilitating side effects characteristic of other cancer drugs," said Cobleigh.

With TDM-1, patients did not even lose their hair and experienced far fewer other side effects.

"This really can have an impact on patient's lives," said Cobleigh.

About 1,000 patients with HER-2 positive breast cancer were enrolled in the Phase III, randomized, multicenter, trial of TDM-1. One group of patients received TDM-1 and the other group received two standard chemotherapy drugs. The TDM-1 patients remained cancer-free for 9.6 months -- progression-free survival -- while the standard treatment group was cancer-free for 6.4 months. Progression-free survival is the time that elapses between the start of a treatment and the time the cancer gets worse.

"This therapy has shown to be effective when other standards treatments have stopped working," said Cobleigh. "For men and women, the treatment gave them the opportunity to lead normal lives."

For more information about the drug therapy being offered at Rush, please contact the Rush Comprehensive Breast Cancer Center at (312) 563-2325.


Story Source:

The above story is based on materials provided by Rush University Medical Center. Note: Materials may be edited for content and length.


Cite This Page:

Rush University Medical Center. "New more effective treatment option for breast cancer patients approved by FDA." ScienceDaily. ScienceDaily, 22 February 2013. <www.sciencedaily.com/releases/2013/02/130222120705.htm>.
Rush University Medical Center. (2013, February 22). New more effective treatment option for breast cancer patients approved by FDA. ScienceDaily. Retrieved August 28, 2014 from www.sciencedaily.com/releases/2013/02/130222120705.htm
Rush University Medical Center. "New more effective treatment option for breast cancer patients approved by FDA." ScienceDaily. www.sciencedaily.com/releases/2013/02/130222120705.htm (accessed August 28, 2014).

Share This




More Health & Medicine News

Thursday, August 28, 2014

Featured Research

from universities, journals, and other organizations


Featured Videos

from AP, Reuters, AFP, and other news services

Mini Pacemaker Has No Wires

Mini Pacemaker Has No Wires

Ivanhoe (Aug. 27, 2014) Cardiac experts are testing a new experimental device designed to eliminate major surgery and still keep the heart on track. Video provided by Ivanhoe
Powered by NewsLook.com
After Cancer: Rebuilding Breasts With Fat

After Cancer: Rebuilding Breasts With Fat

Ivanhoe (Aug. 27, 2014) More than 269 million women are diagnosed with breast cancer each year. Many of them will need surgery and radiation, but there’s a new simple way to reconstruct tissue using a patient’s own fat. Video provided by Ivanhoe
Powered by NewsLook.com
Blood Clots in Kids

Blood Clots in Kids

Ivanhoe (Aug. 27, 2014) Every year, up to 200,000 Americans die from a blood clot that travels to their lungs. You’ve heard about clots in adults, but new research shows kids can get them too. Video provided by Ivanhoe
Powered by NewsLook.com
Radio Waves Knock out Knee Pain

Radio Waves Knock out Knee Pain

Ivanhoe (Aug. 27, 2014) Doctors have used radio frequency ablation or RFA to reduce neck and back pain for years. But now, that same technique is providing longer-term relief for patients with severe knee pain. Video provided by Ivanhoe
Powered by NewsLook.com

Search ScienceDaily

Number of stories in archives: 140,361

Find with keyword(s):
Enter a keyword or phrase to search ScienceDaily for related topics and research stories.

Save/Print:
Share:

Breaking News:
from the past week

In Other News

... from NewsDaily.com

Science News

Health News

Environment News

Technology News



Save/Print:
Share:

Free Subscriptions


Get the latest science news with ScienceDaily's free email newsletters, updated daily and weekly. Or view hourly updated newsfeeds in your RSS reader:

Get Social & Mobile


Keep up to date with the latest news from ScienceDaily via social networks and mobile apps:

Have Feedback?


Tell us what you think of ScienceDaily -- we welcome both positive and negative comments. Have any problems using the site? Questions?
Mobile: iPhone Android Web
Follow: Facebook Twitter Google+
Subscribe: RSS Feeds Email Newsletters
Latest Headlines Health & Medicine Mind & Brain Space & Time Matter & Energy Computers & Math Plants & Animals Earth & Climate Fossils & Ruins